Human Interleukin 6 (also known as MGI2-A; MGI2A; HGF; BSF2; HSF; IFNB2; B-Cell Stimulatory Factor-2; Hybridoma/Plasmacytoma Growth Factor; Hepatocyte Stimulating Factor; Cytotoxic T-Cell Differentiation Factor) is a cytokine involved in inflammation and primarily generated at areas of inflammation in the body, either acute or chronic.1 An IL6 response can be either pro-inflammatory or anti-inflammatory, depending on where activation and signaling occurs; in monocytes or macrophages, the response is pro-inflammatory, and in muscle tissue, it is anti-inflammatory.2 As IL6 is involved in the inflammation response and auto-immune process, it can be found in response to a variety of different diseases including diabetes,3 rheumatoid arthritis4, and Alzheimer’s disease.5 Recently, COVID-19 (caused by SARS-COV-2), has been shown to induce Cytokine Release Syndrome, or a ‘Cytokine Storm,’ in many patients, in which IL6 has an important role.6


Many patients critically ill with COVID-19 die as a result of an excessive immune system response, in particular, the excessive release of cytokines that can result in systemic inflammation in the body and multi-system organ failure.7 This dysfunction of the immune system has been shown to be driven by IL6.7 The two important features of this immune system dysfunction are an excess of pro-inflammatory cytokines and the dysregulation of lymphocytes.7 As IL6 has a key role in indicating and initiating immune system dysfunction in COVID-19 patients, anti-IL6 or IL6 blocker drugs have been recently used in clinical trials to help mitigate the inflammatory response.6,8


Reddot Biotech is pleased to offer a Human Interleukin 6 ELISA kit in both our traditional and Ready-To-Use formats. Our Human IL6 kits have a picogram range (detection range 7.812-500pg/mL; sensitivity 3.11pg/mL) and are suitable for use with a wide variety of different sample types. For more information and to see the product manual, visit our product pages for RDR-IL6-Hu and RD-IL6-Hu. For any other questions, please feel free to contact us.



References and further reading:

  1. IL6 interleukin 6 [Homo sapiens (human)] - Gene - NCBI. (n.d.). Retrieved September 11, 2020, from
  2. Brandt, C., & Pedersen, B. K. (2010). The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. Journal of Biomedicine and Biotechnology2010.
  3. Kristiansen, O. P., & Mandrup-Poulsen, T. (2005). Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes54(suppl 2), S114-S124.
  4. Nishimoto, N. (2006). Interleukin-6 in rheumatoid arthritis. Current opinion in rheumatology18(3), 277-281.
  5. Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer's disease. Biological psychiatry68(10), 930-941.
  6. Magro, G. (2020). SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the'culprit lesion'of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine: X, 100029.
  7. Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., ... & Ntaganou, M. (2020). Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell host & microbe.
  8. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) - Full Text View. (n.d.). Retrieved September 11, 2020, from


Never miss an update.

Sign up for our monthly newsletter to hear about exclusive sales and product tips and tricks.

Your item has been successfully added to your cart.

Item # Price
Proceed to Cart